CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
Year: 2026
Type: preprint
Abstract: Background CNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. Objectives To evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results In this exploratory post hoc analysis of the VISIONARY randomised placebo-controlled trial, CLTE was quantified from serial FLAIR MRI. Fifty-five participants were included (CNM-Au8, n=40; placebo, n=15). Compared with placebo, CNM-Au8 was associated with lower lesion expansion rate (p=0.001; Cliff’s δ=™0.58) and volume (p<0.001; Cliff’s δ=™0.65). Conclusions CNM-Au8 treatment was associated with substantially reduced chronic lesion tissue expansion.
Source: medRxiv
Institutions: The University of Sydney, Macquarie University, Austin Hospital, Austin Health, John Hunter Hospital, University of Newcastle Australia, The University of Western Australia, Perron Institute for Neurological and Translational Science, Princess Alexandra Hospital, The Alfred Hospital, Monash University, University of Tasmania, Menzies Institute for Medical Research, Royal Adelaide Hospital, Royal Prince Alfred Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7214341124